Companies › Samuel Fortin
1 active drug program in 1 registered trial: 1 Phase 4; Psychiatry; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Monoglyceride Eicosapentaenoic acid (MAG-EPA) Omega-3 fatty acid that activates free fatty acid receptors and reduces inflammation throu | FFAR1, FFAR4 | Phase 4 | Brain Fog | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06695910 | Monoglyceride Eicosapentaenoic acid (MAG-EPA) | Phase 4 | Brain Fog | Psychiatry | May 2027 |
ProofPilot Oui Therapeutics Taysha Gene Therapies Gedeon Richter Biomed Industries
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.